The data discussed in this brief review indicate that GPBAR1 and FFARs 1, 2, 3 and 4 all represent potential pharmacological targets for improving impaired glucose homeostasis in type-2 diabetes and related metabolic disorders. Here, GPBAR1 is linked to Other metabolic disease.